MDxHealth recently announced it has signed an agreement to include its recently acquired SelectMDx prostate cancer test in a prospective clinical trial at The Netherlands' Radboud University Medical Center.The study is looking at the effectiveness of new technologies in prostate cancer testing.

The 4M clinical study of 600 test subjects will evaluate the effectiveness of the PCR-based SelectMDx epigenetic test in tandem with magnetic resonance imaging to suggest patients for prostate biopsies. SelectMDx uses gene methylation profiles derived from urine samples to identify patients with a low risk of developing prostate cancer.

Financial and other details of the agreement were not disclosed.MDxHealth gained the rights to the CE-marked test last month when it purchased Radboud University Medical Center spinout NovioGendix for $8.8 million.In August, MDxHealth signed an agreement with The Netherlands' Erasmus University Medical Center giving the firm exclusive worldwide rights to methylation biomarkers for bladder cancer.